November 12, 2025 — This is a perilous and exciting time for investing in obesity innovation as the market for treating this disease advances dramatically. On the side of excitement, we note that the David Wainer in the Wall Street Journal predicts that “obesity drugs are about to go mass market.” Perilous for Novo On the side of peril, […]
November 11, 2025 — Just skimming headlines about new medicines for obesity and surgery, comparisons seem to be a dominant theme. Some of these headlines tell us surgery is more cost-effective or delivers more durable results. Some of that is certainly true. But the deeper truth surfaces this week in JAMA and JAMA Network Open. Clinical experience and, increasingly, […]
November 10, 2025 — At a press event last week, announcing a deal to make obesity medicines more affordable, CMS Administrator Mehmet Oz told us “Americans will lose 135 billion pounds by the midterms” because of this. Comedian Stephen Colbert pointed out a problem with the numbers. They imply that every single American will be losing 393 pounds. It […]
November 8, 2025 — This has been quite a week and the ideas we take home from ObesityWeek 2025 come from both inside and outside of the event in Atlanta. It is a reflection of the fact that the work of cloistered insiders in obesity is and will continue to have large effects in the larger world outside of […]
November 6, 2025 — At ObesityWeek in Atlanta, people are speculating about innovations that health professionals in general practice can embrace widely. We’re getting a good look at two candidates to become the GP GLP-1. Providing real obesity care and prescribing these medicines for more than a small portion of patients who need them is far from the norm. […]
November 5, 2025 — On the opening day of ObesityWeek yesterday, we got quite a treat in a passionate debate of the Lancet Commission report on clinical obesity. Four of our favorite people – Sue Yanovski, Bob Kushner, Fatima Cody Stanford, and Donna Ryan – participated and made it memorable. We walked away with a clear understanding that many […]
November 4, 2025 — It was remarkable and much needed. On the pre-convention day for ObesityWeek in Atlanta, ADA, OAC, and TOS began work to collaborate on models for obesity care that will begin to deliver on a scale that matches the urgency and scope of unmet medical need. TOS Vice-President Jonathan Purnell described the urgency of this to […]
November 3, 2025 — A year ago, we had these wonderful new obesity medicines – semaglutide and tirzepatide – and nobody could get them. Demand had outstripped supply and we had a shortage. Earlier this year, the supply shortage for both drugs resolved, but now we face the same situation because of a different shortage. There is a shortage […]
November 2, 2025 — The headlines won’t stop. “Obesity rates are falling and it’s almost certainly because of Ozempic,” says the Futurism banner. Vox tells us “the Ozempic effect is finally showing up in obesity data.” So can it be true that use of GLP-1s is lowering obesity prevalence? The short answer is no. Not now. Probably not ever. […]
November 1, 2025 — We’re packing our bags and scanning the meeting app for ObesityWeek in Atlanta, November 4-7. This promises to be a very intense week, with the biggest attendance yet for this signature meeting of the Obesity Society. The agenda for the week has a lot of options and we are still processing them all. But for […]
